The small intestine is traditionally viewed as an organ that mediates nutrient digestion and absorption. This view has recently been revised owing to the ability of the duodenum to sense nutrient influx and trigger negative feedback loops to inhibit glucose production and food intake to maintain metabolic homeostasis. Further, duodenal nutrient-sensing defects are acquired in diabetes and obesity, leading to increased glucose production. In contrast, jejunal nutrient sensing inhibits glucose production and mediates the early antidiabetic effect of bariatric surgery, and gut microbiota composition may alter intestinal nutrient-sensing mechanisms to regain better control of glucose homeostasis in diabetes and obesity in the long term. This perspective highlights nutrient-sensing mechanisms in the gut that regulate glucose homeostasis and the potential of targeting gut nutrient-sensing mechanisms as a therapeutic strategy to lower blood glucose concentrations in diabetes.
Diabetes affects approximately 350 million people (1) and is characterized by a disruption in glucose homeostasis. The elevation of plasma glucose concentration is due secondarily to an elevation of hepatic glucose production and a decrease in glucose uptake. Since the discovery of insulin, laboratories have focused on characterizing signaling pathways in the liver that mediate the ability of insulin to inhibit glucose production and in the muscle and fat to increase glucose uptake (2). These studies have convincingly illustrated that reversing insulin resistance and/or enhancing insulin action directly in the liver, muscle, and fat helps restore glucose homeostasis in diabetes and obesity. However, is insulin resistance a dominant determinant of glucose disturbance in diabetes and obesity? Or more specifically, is reversing insulin resistance the most effective way to lower glucose production in diabetes and obesity?
Although the answer to these questions remains unclear, recent studies begin to suggest this may not be the case because administration of leptin is sufficient to lower glucose production and plasma glucose concentrations in insulin-deficient diabetic rodents (3–5). Further, duodenal-jejunal bypass (DJB) surgery lowers glucose production in insulin-deficient uncontrolled diabetic rodents independent of a rise in plasma insulin concentrations (6), whereas in insulin-resistant Zucker fa/fa rodents DJB lowers glucose production independent of reversing insulin resistance (7). The effect of leptin to lower glucose concentrations in insulin-deficient conditions has been attributed to a lowering of plasma glucagon levels (3), implicating glucagon action (instead of insulin resistance) as a potential major driver of hyperglycemia (8). However, the glucose-lowering effect induced by DJB (6) as well as central nervous center nutrient-sensing mechanisms (9) occur independent of changes in plasma glucagon levels, suggesting that other factor(s) responsible for the glucose-lowering effect may be present. In this article, we propose that activating nutrient-sensing mechanisms in the gut is an effective strategy to lower glucose production and plasma glucose concentrations in diabetes and obesity. Further, we postulate that insulin action is not required for the metabolic control of gut nutrient sensing such that glucose homeostasis could be rapidly restored in spite of insulin resistance in diabetes and obesity.
Nutrient-sensing mechanisms in the duodenum
A rise in nutrients occurs in the small intestine after meal ingestion, and nutrients are released into the circulation after their absorption. While still in the preabsorptive state, nutrients activate sensing mechanisms in the duodenum to trigger a gut-brain–driven negative feedback system to inhibit exogenous nutrient intake and endogenous nutrient production by the liver (10–12). Consequently, metabolic homeostasis is maintained in response to nutrient intake. In diabetes and obesity, intestinal nutrient-sensing mechanisms fail to lower food intake and glucose production (13), leading to a disruption in metabolic homeostasis. With an aim to restore glucose and energy homeostasis, laboratories have focused on characterizing duodenal nutrient-sensing mechanisms that alter food intake and glucose production in diabetes and obesity.
This article will first highlight the role of duodenal nutrient-sensing mechanisms in the regulation of glucose homeostasis and its relevance in diabetes and obesity. After the absorption of nutrients such as lipids into duodenal enterocytes, long-chain fatty acids (LCFAs) from lipids are metabolized into LCFA-CoA via acyl-coA synthase (12). Short-term continuous intraduodenal intralipids infusion elevates duodenal LCFA-CoA levels and lowers glucose production in healthy rodents while plasma insulin concentrations are maintained at basal levels (14) (Fig. 1). Direct inhibition of duodenal acyl-coA synthase and accumulation of duodenal LCFA-CoA negates the glucoregulatory effect of intralipids, and intraduodenal lipid infusion also fails to lower glucose production in high-fat diet–fed rodents (14). These findings illustrate the importance of elucidating the downstream duodenal lipid signaling events that regulate glucose production in normal and high-fat diet–fed rodents.
Intraduodenal lipid administration lowers food intake in rodents and humans through the release of the gut-derived peptide hormone cholecystokinin (CCK) from the duodenal I cells (11). The release of CCK induced by LCFA is confirmed in the STC-1 CCK-secreting cell line and is protein kinase C (PKC) dependent (15,16). Along with this, activation of duodenal mucosa PKC (particularly PKC-δ, expressed in both rodent and human duodenal mucosa) by PKC activator is sufficient to lower glucose production while molecular and chemical inhibition of duodenal PKC-δ negate the glucoregulatory effect of duodenal lipids (17). Further, given that direct inhibition of intestinal CCK-1 receptors negates the ability of intraduodenal lipids, PKC activator, or CCK-8 infusion to lower glucose production, the subsequent activation of duodenal CCK-1 receptors is required for the LCFA–PKC-δ–CCK signaling axis to lower glucose production in healthy rodents in vivo (17–19) (Fig. 1). It is believed that CCK binds to the CCK-1 receptors expressed on vagal afferents innervating the small intestine (20), and activation of CCK-1 receptors triggers a gut-brain-liver axis to lower glucose production in healthy rodents (19). Although PKC-δ is colocalized with CCK in the duodenal mucosa (18), suggesting that the LCFA-CoA ➔ PKC-δ ➔ CCK signaling event takes place in the duodenal I-cells, definitive in vivo experiments are lacking. Nonetheless, direct activation of the duodenal PKC-δ ➔ CCK signaling axis fails to lower glucose production in high-fat diet–fed rodents independent of changes in the duodenal expression of CCK-1 receptors (18,19,21).
Addressing the mechanism(s) underlying duodenal PKC-δ ➔ CCK resistance in lowering glucose in high-fat diet is essential for 1) evaluating novel fatty acid G-protein receptors coupled to PKC-δ in duodenal I cells and 2) in evaluating CCK-1 receptor agonists as antidiabetic therapies. In healthy volunteers, it has also been reported that CCK is released in response to intragastric fatty acids with chain lengths matching the ligand profiles of GPR40/FFAR1 and GPR120/O3FAR1, both of which have been shown to be present in rodent duodenal I cells and to modulate CCK release (22,23). GPR40 and GPR120 are both Gq-coupled receptors activating PKC, but is unknown if these receptors lower glucose production via a duodenual-brain-liver axis in rodents on a high-fat diet or if present in human I cells. Recent advances in isolation of human enteroendocrine cells and measuring peptide secretion will directly address the latter (24). Despite the earlier promising potential of CCK-1 receptor agonists in metabolism, selective activation of the receptor has failed to generate a new class of antiobesity or diabetic therapy primarily due to toleration and lack of efficacy. Systemic agonists must be minimized to avoid unwanted adverse effects via direct activation on the gall bladder and pancreas, whereas gut-selective approaches have also been dose limited as a result of gastrointestinal side effects such as vomiting (25). Understanding the endogenous CCK tone within the duodenum in addition to a deeper understanding of the CCK-1 receptor intracellular coupling mechanisms underlying glucose-lowering efficacy may provide new insights into the doability of CCK-1 receptor agonists for diabetes.
CCK-1 receptors are G-protein coupled and are highly expressed in the gut (26). The signaling cascade of CCK-1 receptors in the acinar cells involves both protein kinase A (PKA) and phospholipase C (PLC) activation, which mediate CCK’s ability to trigger pancreatic secretion (26–29). Although the CCK-1 receptor signaling cascade in the duodenum remains largely undefined, direct activation of duodenal PKA signaling has recently been demonstrated to be sufficient and necessary for CCK-1 receptor activation to stimulate vagal afferent firing in vivo (21). Consequently, a gut-brain-liver–driven neuronal network is ignited to lower glucose production in both normal and high-fat diet–fed rodents (21). However, duodenal PKA is not the sole mediator of this network as inhibition of PLC prevents CCK from lowering glucose production as well (21). Given that direct duodenal PKA activation bypasses duodenal CCK resistance in high-fed feeding to lower glucose production (21), high-fat diet–induced defects lie within the inability of duodenal CCK-1 receptor activation to stimulate PKA (Fig. 1). Future studies are warranted to clarify the duodenal signaling cascades of the CCK-1 receptor that regulate glucose production such that novel and effective antidiabetic therapeutic targets could be revealed.
Recently, it has been shown that glucose sensing in L-cells, enterochromaffin cells and activation of neural pathways is impaired in diabetes as determined using phosphorylated calcium calmodulin-dependent kinase II as a marker of cellular activation in vivo (30). No changes were detected in gastric inhibitory peptide (GIP) however. GIP secretion is primarily regulated by fats and was not tested (30,31). Could activation of duodenal PKA signaling mediate other gut-derived peptide hormones such as glucagon-like peptide-1 (GLP-1) and GIP to lower glucose levels in diabetes and obesity? GLP-1 and GIP receptors signal via PKA (32,33), and selective inhibition of intestinal dipeptidyl peptidase-IV (DPP-IV) activity, which enhances GLP-1 and GIP, can trigger vagal firing and improves glucose homeostasis in diet-induced obese rodents in a GLP-1 receptor–dependent manner (34). The role of GIP has not been directly tested. Although the specific site(s) of GLP-1 action in the gut remain to be clarified, a possibility remains that the local release of intestinal GLP-1 activates GLP-1 receptors expressed on the vagus (32) and triggers a gut-brain–driven system to lower blood glucose levels in diabetes and obesity. Of note, it is unknown how the GLP-1 receptor (34) but not CCK-1 receptor (19,21) signaling in the gut remains intact in diet-induced obesity to lower blood glucose levels. Nonetheless, we propose that PKA signaling (likely located on the vagal terminals that innervate the intestine) mediates multiple gut-derived hormones to trigger a gut-brain–driven system to lower blood glucose levels in diabetes (Fig. 1).
On the one hand, intestinal-specific signaling–targeted research may prove useful to unveil novel antidiabetic targets, but on the other hand, examining whether different types of fatty acids or nutrients other than lipids may trigger the gut-brain axis to lower glucose production may be equally important. CCK signaling in the gut is not only triggered by lipids (19), but also by refeeding (17,19) to regulate glucose production and homeostasis, respectively. Although the ability of the duodenal lipid-sensing pathway to regulate glucose production is assessed under the pancreatic euglycemic clamp conditions to ensure that any changes in glucose metabolism are due primarily to the treatment rather than changes in circulating glucoregulatory hormones, direct inhibition of the duodenal lipid-sensing pathway is also found to disrupt glucose homeostasis following a fasting–refeeding nonclamp protocol (17,19). These findings highlight the physiological relevance of a gut-brain–driven feedback system that is activated by duodenal nutrient sensing after a meal to maintain circulating nutrient homeostasis.
It is currently unknown whether other classes of nutrients, in addition to lipids, regulate glucose production in the proximal intestine. However, duodenal glucose sensing inhibits feeding (35,36) while enteric glucose sensing (37) (which includes intestinal, mesenteric, and hepatoportal sensing systems) or, specifically, jejunal glucose sensing (6) regulates peripheral glucose homeostasis via a gut-brain–driven system. Glucose is absorbed through the proximal intestine into the portal vein where selective portal glucose sensing triggers a gut-brain-liver axis to inhibit glucose production and mediate the glucose-lowering effect of bariatric surgery in high-fat diet–fed mice (38). Hence, the essential glucoregulatory role of nutrient-sensing mechanisms in the gut is highlighted and a possibility emerges that nutrient-sensing mechanisms may be conserved throughout the gut for glucose regulation.
Nutrient-sensing mechanisms in the jejunum
Nutrient absorption occurs predominantly in the duodenum, and it is believed that only under malabsorptive conditions undigested nutrients reach the distal gut (39). However, studies in animals (40–43) and humans (44,45) illustrate that ingested nutrients reach the distal gut during early phases of food ingestion, opening up the possibility that nutrient-sensing mechanisms in the jejunum or ileum are activated shortly after a meal to regulate peripheral metabolic homeostasis. In fact, direct jejunal lipid (46–50) or glucose (47) but not protein (47) administration lowers food intake. The underlying mechanisms of jejunal nutrient sensing remain unclear, but the roles of peptide YY (46,47), GLP-1 (46–48), CCK (46), and/or a gut-brain neuronal axis (46,51,52) have been implicated. Nonetheless, given that jejunal nutrient sensing regulates feeding (46–50) and that, as discussed above, duodenal lipid sensing regulates glucose production (12), a potential glucoregulatory role of jejunal nutrient sensing has been examined as well (6) (Fig. 2).
Direct administration of glucose or lipids (the main sources of food energy) into the jejunum lowers glucose production in the absence of a lowering of food intake (6). The effect of nutrient sensing is ignited within the jejunum since direct inhibition of glucose sensing mechanisms in the duodenum or ileum fails to negate the ability of a jejunal glucose infusion to lower glucose production (6). In addition, an equimolar infusion of glucose into the portal vein, as in the jejunum, fails to lower glucose production (6). These experiments do not exclude the glucoregulatory role of nutrient sensing in the duodenum, ileum, or portal vein but rather illustrate that direct infusion of glucose into the jejunum triggers signaling mechanisms within the jejunum to lower glucose production.
Nutrient sensing in the jejunum appears to share similar mechanisms with the duodenum, since both segments lower glucose production in response to lipids, require the formation of LCFA-CoA, and trigger a gut-brain-liver neuronal relay to lower glucose production (6,53). However, evidence suggests that important differences may exist between the two because direct administration of a PKA agonist (which activates downstream CCK-PKA signaling) into the duodenum, but not the jejunum, lowers glucose production (21), although CCK is also synthesized in the jejunum of animals and humans (54–56) but to a much lower extent (57). Given that CCK mediates duodenal lipid sensing mechanisms via PKA and/or PLC signaling pathways to lower glucose production (53) (Fig. 1), these findings suggest that either jejunal nutrient sensing is not CCK dependent or may potentially signal via the CCK-PLC signaling pathway. This working hypothesis remains to be tested.
Out of all the gut-derived satiety factors studied, apolipoprotein A-IV is principally synthesized and secreted from the jejunum, although its secretion is thought to be specific to lipids and not glucose (11). The potential role of apolipoprotein A-IV in jejunal regulation of glucose homeostasis remains unknown. Similarly, other major distal gut peptides that have documented anorectic effects mediated by the vagus are GLP-1 and peptide YY (58), either of which remain possible mediator(s) in maintaining glucose homeostasis triggered by jejunal nutrient sensing. Future investigation is required to dissect the downstream jejunal signaling pathway(s) of nutrient sensing that regulate peripheral metabolic homeostasis.
Inhibition of the sodium-glucose transporter proteins (SGLTs) in the jejunum negates the ability of intrajejunal glucose administration to lower glucose production (6), indicating that jejunal glucose uptake from the lumen is a necessary step for jejunal glucose sensing to regulate peripheral glucose homeostasis. Since galactose, like glucose, is also absorbed into the intestinal enterocyte from the lumen via the same glucose transporter (59), it would be important to assess whether galactose, at an equimolar concentration of glucose in the jejunum, also lowers glucose production. Another monosaccharide, fructose, is absorbed into the intestine via glucose transporter-5 (59), and the potential glucoregulatory role of fructose sensing in the jejunum deserves future attention. We propose that comparing the glucoregulatory impact of sensing mechanisms potentially triggered by any of these monosaccharides will be crucial in revealing novel nutrient-sensing mechanisms in the jejunum. In parallel, accumulation of jejunal LCFA-CoA is required for intrajejunal lipid administration to lower glucose production (6). Because the accumulation of LCFA-CoA in the brain and the liver are sufficient and necessary to mediate both lipid and glucose sensing mechanisms to regulate hepatic glucose metabolism (60), this raises the possibility that lipid and glucose sensing mechanisms within the jejunum may converge. However, this postulation remains to be confirmed.
In a physiological nonclamp (i.e., glucoregulatory hormones change at will) condition when nutrient-sensing mechanisms are activated by a fasting-refeeding protocol, direct disruption of duodenal nutrient-sensing mechanisms increases plasma glucose levels during refeeding and disrupts glucose homeostasis as compared with rodents with intact duodenal nutrient sensing (17,19). In contrast, in the same experimental conditions, plasma glucose levels are not altered when jejunal nutrient-sensing mechanisms are disrupted (6). These data suggest that the key benefits of nutrient-sensing mechanisms in the jejunum to regulate glucose homeostasis are revealed under conditions in which normal nutrient flow is disrupted, for example, when sections of the upper intestine are removed in cases of intestinal cancer or inflammation (where short bowel resection is recommended) or after bariatric surgery in obese patients. Several key aspects of gut nutrient-sensing mechanisms and the regulation of glucose production have been uncovered, yet several questions remain. First, given the fact that direct nutrient administration into the duodenum or jejunum exerts similar effects on glucose production, would an additive or possibly synergistic effect on glucose control be observed if both duodenal and jejunal nutrient sensing were stimulated in parallel with a matched caloric load? Is there a humoral or neuronal crosstalk between the duodenum and jejunum? Given that the duodenum is exposed to the highest influx of nutrients from the stomach, are duodenal nutrient-sensing mechanisms dominant over jejunal nutrient sensing? If so, what is the functional relevance of jejunal nutrient sensing regarding glucose control?
The concept of a defect in duodenal nutrient sensing resulting in an increase in glucose production raises many fundamental questions when translating to a new antidiabetic therapy. Can duodenal nutrient-sensing defects simply be reversed by diet and exercise? Do the duodenal nutrient-sensing defects trigger the first step in the journey of diabetes or is this defect responsible for a select subset of patients with diabetes who need to be defined? How can defects in duodenal nutrient sensing in patients be identified early as part of an intervention strategy? Pharmacologically, any gut-targeted therapy to lower blood glucose will access both the duodenum and jejunum, so is there a predominant selective gut mechanism of action to sufficiently lower blood glucose in diabetes? Alternatively what combination approaches should be pursued to maximize efficacy while maintaining a well-tolerated safety profile?
Gut nutrient-sensing mechanisms in bariatric surgery
Bariatric surgeries exert a wide range of health benefits (61). Although the primary goal of bariatric procedures is weight loss, for which it is currently the most effective intervention, it also remains the only known treatment to induce remission of type 2 diabetes resulting in euglycemia. Bariatric surgery normalizes blood glucose concentrations in the majority of type 2 diabetic humans independent of weight loss (62–64). Furthermore, the effectiveness on glucose control induced by bariatric surgery is superior to conventional pharmacological therapy and lifestyle modifications (62–64). One additional study even indicates that bariatric surgery induces diabetes remission up to 6 years (65).
Although the effectiveness of bariatric surgery has set the standard for goals in glucose control for nonsurgical treatments, replicating its effect with nonsurgical tools has been relatively unsuccessful. Perhaps this is partly due to the complex interactions of numerous signaling pathways affected by the procedure in combination with the equally complex nature of the targeted diseases. Clearly, diabetes remission induced by bariatric surgery is associated with an enhancement of nutrient delivery to the distal small intestine. Could the enhancement of nutrient flux into the distal small intestine after bariatric surgery lead to an antidiabetic effect (Fig. 3)? Given that both the duodenum and jejunum are independently capable of sensing nutrients and generating a gut-derived signal mediated by vagal nerves to trigger a gut-brain-liver axis to lower glucose production independent of weight loss (as discussed above), a clear possibility remains. This hypothesis is also supported by medical devices that are being investigated as noninvasive alternatives to bariatric surgery. A trial using a novel device that electrically alters the vagal nerve firing as a treatment for morbid obesity reports a fast decrease in fasting plasma glucose within the first week in patients with type 2 diabetes (ENABLE trial; http://ir.enteromedics.com/releasedetail.cfm?ReleaseID=610191). Likewise a tube device that is endoscopically inserted in the gut extending from the duodenum to the proximal jejunum to prevent nutrients being absorbed within this region also reports rapid changes in glucose (http://www.gidynamics.com/endobarrier-overview.php).
DJB, a nonrestrictive experimental form of bariatric surgery (66), lowers glucose levels in nonobese rodents (66) and nonobese/mild-obese humans with type 2 diabetes (67,68) independent of weight loss. This surgical procedure redirects nutrient flow from the stomach to the distal jejunum and thus bypasses the duodenum. Can the enhancement of nutrient flux into the jejunum trigger a neurocircuit to lower glucose levels in diabetes with DJB? First, DJB is performed in two independent rat models in which diabetes is induced by destruction of the pancreatic β-cells by either a toxic injection of streptozotocin or a genetic autoimmune response (BioBreeding rats) (6). The use of these uncontrolled diabetic models enables the assessment of the effects of DJB in a nonobese setting with impaired insulin secretion. Within 2 days, DJB lowers blood glucose concentrations independent of lowering food intake/body weight or increasing insulin secretion in both uncontrolled diabetic models (6). Importantly, direct inhibition of jejunal nutrient-sensing mechanisms disrupts peripheral glucose control triggered by DJB during refeeding (6). Of note, the glucose response during refeeding in the DJB diabetic rodents with or without intact jejunal nutrient-sensing mechanisms closely resembles those observed in relatively mild-obese type 2 diabetic humans with or without DJB surgery, respectively (67). Together with the ability of jejunal nutrient sensing to trigger a gut-brain-liver neuronal relay to lower glucose production in normal rodents (see above), these findings collectively suggest that increased delivery of nutrients to the jejunum after DJB triggers a neuronal-mediated signaling mechanism to lower glucose production and hence blood glucose concentrations in diabetes.
The ability of DJB to rapidly lower blood glucose concentrations is potentially via a CNS-mediated reduction in hepatic glucose production (6). In fact, other reports have published similar results that DJB (7) or a variant of DJB (38) triggers the CNS to lower hepatic glucose production in obese type 2 diabetic rodents. Of note, DJB lowers blood glucose concentrations in insulin-deficient rodents (6) and lowers glucose production in obese type 2 diabetic rodents independent of an improvement on insulin action (7). Thus, we propose that insulin action is not required for the rapid glucose-lowering effect induced by DJB in diabetes. However, these findings do not exclude the possibility that DJB could also lower blood glucose concentrations via increased insulin-dependent or independent glucose uptake, although studies have indicated that DJB does not improve insulin action in rodents with diabetes and/or obesity (7,69,70). In addition, improvement in β-cell function occurs after bariatric surgery in obese type 2 diabetic subjects (61). Thus, a potential increase in glucose uptake, improvement in insulin action and/or increase in insulin secretion could play important roles in the sustained glucose-lowering effect triggered by DJB.
Of note, changes in insulin secretion after bariatric procedures in obese type 2 diabetes are generally thought to coincide with increased GLP-1 secretion (61). However, changes in circulating GLP-1 are not consistent between models of diabetes that received DJB (6). Moreover, bariatric surgery still improves glucose tolerance in GLP-1 receptor–deficient high-fat diet–fed mice (71). In addition, clinical use of GLP-1 agonists and DPP-IV inhibitors does not mirror the full glycemic benefits observed after bariatric surgery, and although controversial, it is possible that other incretin hormones such as GIP may be involved in enhancing insulin secretion.
It is well known that bariatric surgery results in significant health benefits in obesity with type 2 diabetes, whereas only a few studies have demonstrated that bariatric surgery lowers glucose concentrations in mild/nonobese type 2 diabetic subjects (67,68) and in obese type 1 diabetic subjects (72). In clinical practice, there is much debate regarding the appropriate BMI level to determine eligibility for bariatric procedures. Therefore, until this debate is resolved, determining whether bariatric surgery could exert significant benefit in nonobese humans with type 1 diabetes will remain speculative. Despite this, the existence of a gut-brain-liver axis regulating glucose homeostasis and its relevance in the antidiabetic effect of bariatric surgery suggests that targeting the gut with drug therapy to influence the liver could be a valid therapeutic approach and would potentially mimic the antidiabetic effect of bariatric surgery. Given the accessibility of the gut to pharmacotherapy, we propose targeting nutrient sensing molecules in the gut will have therapeutic potential in lowering blood glucose concentrations in diabetes.
Gut microbiota and nutrient sensing
The intestine has developed mechanisms to sense nutrients after a meal and trigger a negative feedback system to maintain glucose homeostasis. This triggering leads to the rapid glucose lowering effect of DJB in diabetes (Figs. 2 and 3). However, we must keep in mind that the intestinal environment is complex, given that an abundant collection of microorganisms (predominantly bacteria) termed microbiota resides within the gut. In the human intestine approximately 400 bacterial species are present and together resemble a multicellular organ that has evolved to provide metabolic functions (73). These bacteria belong to three main groups (phyla): Firmicutes, Bacteriodetes, and Actinobacteria, which represent >95% of the total bacteria in the intestine. Disruption in this symbiotic relationship can disturb host functions and in extreme cases can cause serious disease such as irritable bowel disease (74), stressing the importance of these microorganisms in maintaining the intestinal environment and the roles they play in helping the host.
The gut microbiota is a dynamic organ that is constantly adapting to changes in its environment, and it is believed that the progression of obesity/diabetes can be attributed to the intestinal microbiota–host relationship. In mice switched from a regular chow to a high-fat diet, the gut microbiota composition is altered in as little as 24 h (75), resulting in increased levels of Firmicutes (76). This change is secondary to increased fat content rather than the obese state, rendering the microbiota to be more obesogenic and resulting in increased energy harvest from the diet in the distal gut. In addition, germ-free mice are protected from developing diet-induced obesity (77), further highlighting the relationship between the gut microbiome and obesity. Of note, it has recently been demonstrated that genetically identical mice fed the same high-fat diet differed in their metabolic phenotype due to differences in their microbiota composition (78). Thus, the relative contribution of diet versus the gut microbiota profile in causing metabolic diseases remains to be addressed.
Although a larger bacterial population resides in the more distal portion of the small intestine and in the colon, bacteria are also present in the upper intestine, including the duodenum and jejunum. In fact, direct administration of microbiota from lean donors into the duodenum of humans with metabolic syndrome significantly improves insulin sensitivity independent of weight loss (79), consistent with the view that the duodenum regulates peripheral glucose homeostasis (Fig. 1). Furthermore, gut microbiota alters intestinal permeability (80,81) and regulates both the synthesis and production of bile acids (82,83), which are important for fat emulsification and absorption in the intestine. Gut microbiota also regulates hormone release from enteroendocrine cells (84,85) and interestingly, ingestion of bacteria activates vagal afferent signaling (86). In addition, germ-free mice have altered CD36 expression (a proximal fatty acid transporter) (85) and SGLT-1 expression (84), indicating that gut bacteria affects nutrient absorption/uptake. Further, high-fat feeding promotes an obesogenic bacterial profile, which is linked to increased inflammation in the intestine and whole-body insulin resistance (80). Obesogenic mirobiota induces inflammation potentially via bacterial fragments (87). In light of these findings, we put forward a working hypothesis that the obesogenic microbiome disrupts nutrient-sensing CCK signaling mechanisms in the duodenum, leading to a dysregulation of glucose homeostasis (Fig. 1).
Changes in microbiota also occur after bariatric surgery in which the obese bacterial profile is altered to reflect a more lean profile (88). Whether these changes are associated with a decrease in food intake or are due to the physical rearrangement of the digestive tract still remains unknown. It has also been suggested that this change in microbiota after surgery may lead to changes in enteroendocrine cell function (85,89). However a direct correlation has not been shown. Thus, the link between bariatric surgery and changes in gut microbiota as well as its eventual impact on metabolic regulation warrants further investigation. Nevertheless, a possibility remains that the improvement of glucose homeostasis observed following bariatric surgery is mediated by a change in gut microbiota, leading to an enhancement of nutrient-sensing mechanisms in the jejunum and an improvement in glucose tolerance (Fig. 3).
The gut possesses a unique role in regulating glucose and energy homeostasis whereby the presence of ingested nutrients into the small intestine activates sensing mechanisms that affect both glucose production and food intake. The nutrient-sensing mechanisms are conserved from the duodenum to the jejunum, and although it is evident that nutrient uptake and a neuronal network are required in both regions to lower glucose production, whether additional parallel mechanisms exist is not yet known. Duodenal nutrient sensing acts as a protective mechanism under normal physiological conditions to maintain glucose homeostasis during nutrient ingestion by ensuring that glucose production is decreased; however, this mechanism appears to be impaired after excess caloric intake. On the other hand, jejunal nutrient sensing is important in mediating the glucose lowering effect (via decreased glucose production) of bariatric surgery where nutrient influx to the jejunum is enhanced. Emerging evidence also suggests a relationship between gut microbiota and intestinal nutrient-sensing mechanisms; however, this concept has not been directly tested. Although many questions remain unanswered, recent advances in our understanding of the pathways regulating gut nutrient sensing provide compelling support for potential new therapeutic targets to restore glucose homeostasis in diabetes.
The work discussed in this review from the Lam laboratory is supported by a research grant from the Canadian Institute of Health Research (CIHR-MOP-82701). D.M.B. was supported by a Canadian Diabetes Association postdoctoral fellowship. B.A.R. was supported by a CIHR Doctoral Vanier Canada scholarship.
No potential conflicts of interest relevant to this article were reported.
D.M.B., B.A.R., C.D.C., and T.K.T.L. developed the concept and wrote the manuscript. V.M.J. reviewed and edited the manuscript.
The authors apologize to colleagues whose work is not referenced as the result of space limitations.
D.M.B. is currently affiliated with Pfizer Global Research and Development, Cambridge, Massachusetts.
- Received April 2, 2013.
- Accepted May 20, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.